Project Grant HT94252410950

The Department of the Army Medical Command awarded a $1,657,861 project grant to H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. to develop adoptive T-cell therapy incorporating patient-specific tumor microenvironments for the treatment of bladder cancer. The grant was awarded on September 1, 2022 under the Military Medical Research and Development program (CFDA 12.420) and will support research activities through August 31, 2026. The Military Medical Research and...

The National Cancer Institute awarded a $1,542,555 Project Grant to Sloan-Kettering Institute For Cancer Research under the Cancer Treatment Research program (CFDA 93.395). The grant will fund research from December 2022 through November 2027 to develop more effective treatments for localized bladder cancer. Specifically, the grantee will conduct genomic analyses of bladder cancer patient cohorts to validate DNA damage response mutations as predictors of sensitivity to bacillus Calmette-Guérin...

The National Cancer Institute (NCI) awarded a $712,735 Project Grant under the Cancer Treatment Research (CFDA 93.395) program to the University of Southern California (USC) on June 1, 2025. This grant will fund a Phase II clinical trial to evaluate the efficacy of a combination therapy using the novel agent SEPHB4-HSA, an EphrinB2 inhibitor, and the PD-1 antibody Pembrolizumab in urothelial carcinoma (bladder cancer) patients whose tumors express EphrinB2 and have low/non-expressing Nectin4...

The H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. was awarded a $857,516 project grant from the Department of the Army Medical Command under the Military Medical Research and Development program. The grant will fund the development of adoptive T-cell therapy incorporating patient-specific tumor microenvironments to treat bladder cancer from September 1, 2022 to August 31, 2026. Through this funding, Moffitt Cancer Center will work to transform bladder cancer treatment by...

H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. was awarded a $1,193,945 project grant from the Department of the Army Medical Command under the Military Medical Research and Development program. The grant will fund development of adoptive T-cell therapy incorporating patient-specific tumor microenvironments to treat bladder cancer from September 1, 2022 to August 31, 2026. The Military Medical Research and Development program supports biomedical research that transforms...

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $583,973.00 to the Sloan-Kettering Institute for Cancer Research to investigate the role of EP300 mutations in bladder cancer pathogenesis and drug response. The key objectives are to: Study how EP300 loss-of-function mutations mediate resistance to FGFR inhibitors like erdafitinib using patient-derived bladder cancer models. Identify genomic alterations, especially EP300...

The University of North Carolina at Chapel Hill (UNC-CH) received a $514,582 Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct research on "Targeting APOBEC3-Induced Squamous Differentiation in Bladder Cancer". The award began on March 1, 2025 and is set to conclude on February 28, 2030. The research aims to investigate the role of APOBEC3 enzymes in bladder cancer initiation and progression,...

This $2,108,734 Project Grant was awarded on September 1, 2025 by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to The University of Texas M.D. Anderson Cancer Center to conduct a 5-year research program focused on bladder cancer. The key objectives of this research program are: 1) Developing molecular profiles of bladder cancer evolution from field effects to aggressive disease, and investigating the role of LPAR6 and CAB39L in dysregulating urothelial...

The National Cancer Institute (NCI) awarded a $215,311 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of Texas Health Science Center at Houston (UTHealth) for the project "Preclinical Efficacy of GPR56 Antibody-Drug Conjugates and Combination Therapies for Triple-Negative Breast Cancer". The 24-month grant aims to develop and evaluate GPR56 antibody-drug conjugates (ADCs) as a novel targeted therapy for triple-negative breast cancer (TNBC),...

The National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) awarded a $452,540 Project Grant to the Sloan-Kettering Institute for Cancer Research to develop novel T-cell imaging techniques to better understand therapy resistance and treatment efficacy of bispecific T-cell engager (BiTE) antibodies targeting B-cell maturation antigen (BCMA) and G protein coupled receptor class C group 5 member D (GPRC5D) in relapsed and refractory multiple myeloma patients. The...